-
公开(公告)号：EP1773788A2
公开(公告)日：2007-04-18
申请号：EP05768294.0
申请日：2005-07-26
申请人： NOVARTIS-PHARMA GMBH , Novartis AG
发明人： FLOERSHEIM, Philipp , ALLGEIER, Hans , FROESTL, Wolfgang , KOLLER, Manuel , MATTES, Henri , NOZULAK, Joachim , OFNER, Silvio , ORAIN, David , RASETTI, Vittorio , RENAUD, Johanne , SOLDERMANN, Nicolas
IPC分类号： C07D239/96 , C07D403/04 , C07D409/12 , C07D401/12 , A61K31/517 , A61P25/00 , A61P25/18 , A61P25/28
CPC分类号： C07D409/12 , C07D239/96 , C07D401/12 , C07D403/04
摘要： The present invention relates to 1H-Quinazoline-2,4-dione derivatives of formula (I) wherein the substituents are defined as in the specification, their preparation, their use as pharmaceuticals, and pharmaceutical compositions containing them.
摘要翻译： 本发明涉及其中取代基如说明书中所定义的式（I）的1H-喹唑啉-2,4-二酮衍生物，它们的制备，它们作为药物的用途以及含有它们的药物组合物。
-
公开(公告)号：EP3024827B1
公开(公告)日：2020-04-15
申请号：EP14829331.9
申请日：2014-07-24
申请人： Novartis AG
发明人： DU, Zhenxing , HINTERMANN, Samuel , HURTH, Konstanze , JACQUIER, Sebastien , LEHMANN, Hansjoerg , MOEBITZ, Henrik , SOLDERMANN, Nicolas , STOJANOVIC, Aleksandar
IPC分类号： C07D401/14 , C07D403/14 , C07D417/14 , C07D473/16 , A61K31/517 , A61K31/52 , A61P35/00
-
3.发明公开DIHYDRO-BENZO-OXAZINE AND DIHYDRO-PYRIDO-OXAZINE DERIVATIVES 有权2,3-二氢苯并[1,4]氧杂 - 衍生物磷酸三磷酸激酶3（PI3K）抑制剂ZUR BEHANDLUNG VON RHEUMATOIDER ARTHRITIS
公开(公告)号：EP2794600A1
公开(公告)日：2014-10-29
申请号：EP12823036.4
申请日：2012-12-20
申请人： Novartis AG
发明人： CARAVATTI, Giorgio , CHAMOIN, Sylvie , FURET, Pascal , HÖGENAUER, Klemens , HURTH, Konstanze , KALIS, Christoph , KAMMERTOENS, Karen , LEWIS, Ian , MOEBITZ, Henrik , SMITH, Alexander Baxter , SOLDERMANN, Nicolas , WOLF, Romain , ZECRI, Frédéric
IPC分类号： C07D413/14 , C07D498/04 , A61K31/536 , A61K31/5365 , A61P19/02 , A61P37/08 , A61P35/00 , A61P33/06
CPC分类号： A61K31/5383 , A61K31/538 , C07D413/14 , C07D498/04 , C12N9/12 , C12Q1/25 , C12Q1/686 , Y02A50/409 , Y02A50/411
摘要： The invention relates to dihydro-benzo-oxazine and dihydro-pyrido-oxazine compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof, wherein Y, V, W, U, Q, R1, R5, R7 and R30 are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.
摘要翻译： 本发明涉及式（I）的二氢 - 苯并恶嗪和二氢 - 吡啶并 - 恶嗪化合物和/或其药学上可接受的盐和/或溶剂合物，其中Y，V，W，U，Q，R 1，R 5，R 7 和R30如说明书中所定义。 此类化合物适用于治疗由PI3K酶的活性介导的疾病或疾病。
-
公开(公告)号：EP1773788B8
公开(公告)日：2013-01-09
申请号：EP05768294.0
申请日：2005-07-26
申请人： Novartis AG
发明人： FLOERSHEIM, Philipp , ALLGEIER, Hans , FROESTL, Wolfgang , KOLLER, Manuel , MATTES, Henri , NOZULAK, Joachim , OFNER, Silvio , ORAIN, David , RASETTI, Vittorio , RENAUD, Johanne , SOLDERMANN, Nicolas
IPC分类号： C07D239/96 , C07D403/04 , C07D409/12 , C07D401/12 , A61K31/517 , A61P25/00 , A61P25/18 , A61P25/28
CPC分类号： C07D409/12 , C07D239/96 , C07D401/12 , C07D403/04
-
公开(公告)号：EP2928896B1
公开(公告)日：2017-07-19
申请号：EP13824177.3
申请日：2013-11-26
申请人： NOVARTIS AG
发明人： HURTH, Konstanze , KALIS, Christoph , KAMMERTOENS, Karen , SOLDERMANN, Nicolas , ZECRI, Frédéric
IPC分类号： C07D498/04 , A61K31/5365 , A61P29/00
CPC分类号： C07D498/04
摘要： The invention relates to an anhydrous crystalline form of (1,1-dioxo-hexahydro-1lambda*6*- thiopyran-4-yl)-{(S)-3-[1-(6-methoxy-5-methyl-pyridin-3-yl)-2,3-dihydro-1H-pyrido[3,4- b][1,4]oxazin-7-yloxy]-pyrrolidin-1-yl}-methanone; pharmaceutical compositions and combinations including these forms as well as to methods of using these forms, including their pharmaceutical compositions and combinations for the treatment of diseases.
摘要翻译： 本发明涉及（1,1-二氧代 - 六氢-1λ* 6 * - 噻喃-4-基） - {（S）-3- [1-（6-甲氧基-5-甲基 - 吡啶并[ -3-基）-2,3-二氢-1H-吡啶并[3,4-b] [1,4]恶嗪-7-基氧基] - 吡咯烷-1-基} - 甲酮; 包括这些形式的药物组合物和组合以及使用这些形式的方法，包括它们的药物组合物和用于治疗疾病的组合。
-
6.发明公开SOLID FORMS AND SALTS OF TETRAHYDRO-PYRIDO-PYRIMIDINE DERIVATIVES 审中-公开固态形式，以及TETRA HYDRO-吡啶并嘧啶衍生物的盐
公开(公告)号：EP2723740A1
公开(公告)日：2014-04-30
申请号：EP12738616.7
申请日：2012-06-25
申请人： Novartis AG
发明人： FERNANDES GOMES DOS SANTOS, Paulo Antonio , HÖGENAUER, Klemens , HOLLINGWORTH, Gregory , SOLDERMANN, Nicolas , STOWASSER, Frank , TUFILLI, Nicola , ZECRI, Frédéric
IPC分类号： C07D471/04 , A61K31/517 , A61P29/00
CPC分类号： C07D471/04
摘要： The invention relates to crystalline anhydrous forms, crystalline solvate forms and/or salt forms including crystalline salt forms of {(S)-3-[6-(6-methoxy-5-methyl-pyridin-3-yl)-5,6,7,8- tetrahydro-pyrido[4,3-d]pyrimidin-4-yloxy]-pyrrolidin-1-yl}-(tetrahydro-pyran-4-yl)-methanone or salt forms including crystalline salt forms of 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl- pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-on; pharmaceutical compositions and combinations including these forms as well as to methods of using these forms, including their pharmaceutical compositions and combinations for the treatment of diseases.
-
7.发明公开2,4'-BIPYRIDINYL COMPOUNDS AS PROTEIN KINASE D INHIBITORS USEFUL FOR THE TREATMENT OF IA HEART FAILURE AND CANCER 审中-公开2,4ý-BIPYRIDINYLVERBINDUNGEN AS心力衰竭和癌症IA合适的蛋白质激酶酶D抑制剂的治疗
公开(公告)号：EP2310381A1
公开(公告)日：2011-04-20
申请号：EP09761792.2
申请日：2009-06-12
申请人： Novartis AG
发明人： BURGIS, Robin , CAPPARELLI, Michael, Paul , DIPIETRO, Lucian , GAMBER, Gabriel, G. , JEWELL, JR., Charles, Francis , MEREDITH, Erik , MIRANDA, Karl , MONOVICH, Lauren, G. , RAO, Chang , SOLDERMANN, Nicolas , YOON,Taeyoung , ZHU, Qingming
IPC分类号： C07D401/04 , C07D401/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D519/00 , A61K31/496 , A61P9/04 , A61P35/00
CPC分类号： C07D401/04 , C07D401/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D519/00
摘要： The present invention provides novel organic compounds of Formula I: methods of use, and pharmaceutical compositions thereof.
-
公开(公告)号：EP4395828A1
公开(公告)日：2024-07-10
申请号：EP22797110.8
申请日：2022-08-30
申请人： Novartis AG
发明人： CHAPEAU, Emilie , CHENE, Patrick , FURET, Pascal , KIEFFER, Laurence , MACHAUER, Rainer , PICARD, Anne , SCHMELZLE, Tobias , SELLNER, Holger , SOLDERMANN, Nicolas , VOEGTLE, Markus , WARTMANN, Markus
CPC分类号： A61K47/545 , A61K47/55 , A61P35/00 , C07D405/12 , C07D417/12 , C07D405/14
-
9.发明授权2,3-Dihydro-benzo[1,4]oxazine derivatives and related compounds as phosphoinositide-3 kinase (PI3K) inhibitors for the treatment of e.g. rheumatoid arthritis 有权作为磷酸肌醇-3激酶（PI3K）抑制剂的2,3-二氢 - 苯并[1,4]恶嗪衍生物和相关化合物用于治疗例如 类风湿关节炎
公开(公告)号：EP2794600B1
公开(公告)日：2017-12-06
申请号：EP12823036.4
申请日：2012-12-20
申请人： Novartis AG
发明人： CARAVATTI, Giorgio , CHAMOIN, Sylvie , FURET, Pascal , HÖGENAUER, Klemens , HURTH, Konstanze , KALIS, Christoph , KAMMERTOENS, Karen , LEWIS, Ian , MOEBITZ, Henrik , SMITH, Alexander Baxter , SOLDERMANN, Nicolas , WOLF, Romain , ZECRI, Frédéric
IPC分类号： C07D413/14 , C07D498/04 , A61K31/536 , A61K31/5365 , A61P19/02 , A61P37/08 , A61P35/00 , A61P33/06
CPC分类号： A61K31/5383 , A61K31/538 , C07D413/14 , C07D498/04 , C12N9/12 , C12Q1/25 , C12Q1/686 , Y02A50/409 , Y02A50/411
摘要： The invention relates to dihydro-benzo-oxazine and dihydro-pyrido-oxazine compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof, wherein Y, V, W, U, Q, R1, R5, R7 and R30 are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.
-
公开(公告)号：EP1773788B1
公开(公告)日：2012-11-14
申请号：EP05768294.0
申请日：2005-07-26
申请人： Novartis AG
发明人： FLOERSHEIM, Philipp , ALLGEIER, Hans , FROESTL, Wolfgang , KOLLER, Manuel , MATTES, Henri , NOZULAK, Joachim , OFNER, Silvio , ORAIN, David , RASETTI, Vittorio , RENAUD, Johanne , SOLDERMANN, Nicolas
IPC分类号： C07D239/96 , C07D403/04 , C07D409/12 , C07D401/12 , A61K31/517 , A61P25/00 , A61P25/18 , A61P25/28
CPC分类号： C07D409/12 , C07D239/96 , C07D401/12 , C07D403/04
-
-
-
-
-
-
-
-
-
搜索结果
22 条记录 (耗时 0.028 秒)
